Mink Therapeutics currently holds 65.42
M in liabilities. This firm has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Mink Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Mink Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mink Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mink Therapeutics to invest in growth at high rates of return. When we think about Mink Therapeutics' use of debt, we should always consider it together with cash and equity.
Mink Therapeutics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Mink Therapeutics, including all of Mink Therapeutics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Mink Therapeutics assets, the company is considered highly leveraged. Understanding the
composition and structure of overall Mink Therapeutics debt and outstanding corporate bonds gives a good idea of
how risky the capital structure of a business is and if it is worth investing in it. Please read more on our
technical analysis page.
Watch out for price decline
Please consider monitoring Mink Therapeutics on a daily basis if you are holding a position in it. Mink Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Mink Therapeutics stock to be traded above the $1 level to remain listed. If Mink Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Understanding Mink Total Liabilities
Mink Therapeutics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Mink Therapeutics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Mink Therapeutics balance sheet include debt obligations and money owed to different Mink Therapeutics vendors, workers, and loan providers. Below is the chart of Mink short long-term liabilities accounts currently reported on its balance sheet.
You can use Mink Therapeutics
financial leverage analysis tool to get a better grip on understanding its financial position
How important is Mink Therapeutics's Liquidity
Mink Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Mink Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Mink Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Mink Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Mink Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Mink Therapeutics's total debt and its cash.
A Deeper Perspective On Mink Therapeutics
Net Loss for the year was (25.98
M).
Liabilities Breakdown
14.9 M
Current Liabilities
48.3 M
Long-Term Liabilities
| Total Liabilities | 63.18 Million |
| Current Liabilities | 14.87 Million |
| Long-Term Liabilities | 48.3 Million |
Our take on Mink Therapeutics to rebound
Newest Risk Adjusted Performance is up to -0.06. Price may drop again. Mink Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Mink Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Mink Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mink Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mink Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Mink Therapeutics Implied Volatility
Mink Therapeutics' implied volatility exposes the market's sentiment of Mink Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mink Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mink Therapeutics stock will not fluctuate a lot when Mink Therapeutics' options are near their expiration.
Our Bottom Line On Mink Therapeutics
Whereas some companies in the biotechnology industry are either recovering or due for a correction, Mink Therapeutics may not be as strong as the others in terms of longer-term growth potentials. The bottom line, as of the 18th of March 2022, we believe that at this point, Mink Therapeutics is
undervalued with
above average probability of distress within the next 2 years. Our primary buy-or-sell advice on the firm is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Mink Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com